BCL2A1 and prostate cancer: (−)‐BI97D6 demonstrated binding inhibition of Bcl‐xL, Bcl‐2, Mcl‐1, and Bfl‐1 with IC50 values of 76, 31, 25, and 122 nm, respectively in FP assays (FITC‐Bak‐BH3‐only peptide).63 Additionally, (−)‐BI97D6 inhibited growth of the PC‐3 human prostate cancer and H23 human lung cancer cell lines with EC50 values of 0.22 and 0.14 μm, respectively.